Welcome to our dedicated page for Microvision SEC filings (Ticker: MVIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to MicroVision, Inc. (NASDAQ: MVIS) SEC filings, offering a centralized view of the company’s regulatory disclosures. Through these documents, investors can review how MicroVision reports on its lidar hardware and perception software business, its activities in automotive, industrial, and defense-related markets, and its corporate governance and financing arrangements.
Key filings for MicroVision include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial results. These reports are particularly relevant for understanding MicroVision’s investment in solid-state lidar technologies, its focus on ADAS and autonomous driving, and its efforts in industrial automation and defense tech. Current reports on Form 8-K provide timely updates on material events, such as leadership changes, executive compensation arrangements, board appointments, and the announcement of quarterly results.
MicroVision’s filings also document corporate actions like the appointment of a new Chief Executive Officer, the designation of an Executive Vice Chair, changes in board composition, and transitions in the Chief Financial Officer role. These disclosures help investors track how the company’s leadership and governance structure evolve alongside its strategic focus on autonomy and mobility.
On Stock Titan, MicroVision’s SEC documents are updated in near real time as they are posted to EDGAR. AI-powered summaries assist readers by highlighting the main points in lengthy filings, including key business updates, segment information where provided, and notable risk or governance items. Users can quickly scan 10-K and 10-Q reports, review 8-K announcements about material events, and access other filings while relying on AI-generated explanations to navigate complex regulatory language more efficiently.
MicroVision, Inc. reported that it received a deficiency notice from Nasdaq on January 12, 2026 because its common stock failed to meet the minimum bid price requirement of $1 per share for the last 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice does not immediately affect the listing or trading of its shares, and the company remains in compliance with all other Nasdaq continued listing standards. MicroVision has 180 days from the notice date to regain compliance and is evaluating available options, while its business operations, SEC reporting, and contractual obligations continue unchanged.
MicroVision, Inc. interim CFO Stephen Hrynewich reported routine equity compensation activity. On January 5, 2026, 4,800 restricted stock units vested and were distributed to him as shares of common stock on a unit-for-share basis at $0.00 per share. These RSUs simultaneously ceased to exist as a derivative position.
On January 6, 2026, the issuer completed a withholding tax-related, nondiscretionary sell-to-cover of 1,573 shares of common stock at a price of $0.9185 per share under the award agreement. After these transactions, Hrynewich directly beneficially owned 156,133 shares of MicroVision common stock.
MicroVision interim CFO reports equity holdings as a company insider. Interim CFO Stephen Hrynewich beneficially owns 152,906 shares of MicroVision common stock directly. In addition, he holds derivative securities in the form of restricted stock units (RSUs) tied to MicroVision common stock.
One RSU grant for 30,000 shares was granted on 11/20/2025 and is scheduled to vest 16% on 1/5/2026, 2/5/2026, 3/5/2026, 4/6/2026, and 5/5/2026, and 20% on 6/5/2026, subject to his continued employment on each vesting date. A separate RSU award for 25,000 shares vests on 09/08/2026. Each RSU represents a contingent right to receive one share of MicroVision common stock at an exercise price of $0.00.
MicroVision, Inc. announced that Chief Financial Officer Anubhav Verma resigned from his position, effective no later than December 31, 2025. The company stated that his resignation did not result from any disagreement regarding financial statements, internal controls, operations, policies, or practices.
To support continuity, the Board appointed Stephen Hrynewich, currently Vice President, Global Finance & Operations, to serve as Interim Chief Financial Officer as of the effective date. Hrynewich was also designated as the company’s principal financial officer and principal accounting officer. MicroVision has begun a search to identify a permanent Chief Financial Officer.
MicroVision (MVIS) CFO equity activity: Chief Financial Officer Anubhav Verma reported the vesting of restricted stock units and related share activity. On 11/17/2025, 16,765 restricted stock units vested and were converted into the same number of common shares at an exercise price of $0.00. On 11/18/2025, 4,225 common shares were disposed of at $0.941 per share in a tax withholding "sell-to-cover" transaction completed by the company under the award terms.
Following these transactions, Verma beneficially owned 499,438 shares of MicroVision common stock in direct ownership, and no restricted stock units remained from this specific award. The filing notes that the RSUs were distributed on a one-for-one share basis and that the tax sale was nondiscretionary, carried out in accordance with the award agreement.
MicroVision, Inc. reporting person Simon Biddiscombe, an Executive Vice Chair and Director, received a grant of 241,000 restricted stock units (RSUs) on 10/01/2025. The RSUs convert unit-for-share at vesting with no cash payment required, and are scheduled to vest in full on 10/01/2026 provided the reporting person continues service through that date. The Form 4 discloses the transaction date as 10/01/2025 and the filing was signed by an attorney-in-fact on 10/02/2025. The report records direct beneficial ownership of 0 common shares following the grant because the RSUs have not yet vested.
MicroVision, Inc. is making a planned leadership change, promoting current Chief Technology Officer Glen W. DeVos to President and Chief Executive Officer and to the Board, effective September 30, 2025. Current CEO Sumit Sharma will serve until that date, after which his removal qualifies as an involuntary termination under the company’s Executive Severance and Change in Control Plan, entitling him to severance upon signing a customary release.
Under a new employment agreement, Mr. DeVos will receive a $530,000 annual base salary, a short-term incentive opportunity equal to 100% of base salary, and a grant of 539,000 RSUs that vest on June 6, 2026 only if specified company and individual objectives are met. The Board plans to set a longer-term equity structure for him in 2026. The Board also named director Simon Biddiscombe as Executive Vice Chair for up to 12 months, with a $265,000 salary and 241,000 RSUs vesting October 1, 2026. During this period he will not be an independent director, and Robert Carlile will become Audit Committee Chair.
MicroVision, Inc. (MVIS) director Jada Smith received 22,007 shares when restricted stock units (RSUs) vested on 09/02/2025 and were distributed on a unit-for-share basis without payment. After the distribution, the reporting person beneficially owned 82,344 shares of common stock directly. The Form 4 also discloses RSUs granted 06/06/2025 that vest in four equal quarterly installments through the earlier of the first anniversary of the grant or the day before the 2026 annual meeting, subject to continued service as a director.
MicroVision director Peter Schabert received 22,007 shares when vested restricted stock units converted to common stock on 09/02/2025. The shares were distributed at $0.00 as vested RSUs convert on a unit-for-unit basis without payment. After the transaction Schabert beneficially owned 102,457 shares. The filing corrects an earlier RSU grant reporting error, noting the original Form 4 misreported totals and that the vesting disclosed here was calculated using a stated “correct” RSU amount. The Form 4 was signed by an attorney-in-fact on behalf of Schabert.
FAQ
What is the current stock price of Microvision (MVIS)?
What is the market cap of Microvision (MVIS)?
